XTL Biopharmaceuticals Ltd (XTLB) stock
XTLBNasdaqPharmaceutical Preparations
$1.62+0.08 (+5.19%)
Close on Nov 17, 2026Market cap $15.33MP/E –Yield –
XTL Biopharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$1.69M. The highest annual figure on record is -$765.00K in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.69M | – |
| FY2024 | Dec 31, 2024 | -$775.00K | – |
| FY2023 | Dec 31, 2023 | -$765.00K | – |
| FY2022 | Dec 31, 2022 | -$880.00K | – |
| FY2021 | Dec 31, 2021 | -$1.03M | – |
| FY2020 | Dec 31, 2020 | -$948.00K | – |
| FY2019 | Dec 31, 2019 | -$842.00K | – |
| FY2018 | Dec 31, 2018 | -$793.00K | – |
| FY2017 | Dec 31, 2017 | -$1.25M | – |
| FY2016 | Dec 31, 2016 | -$2.56M | – |
| FY2015 | Dec 31, 2015 | -$3.61M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$202.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$303.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$217.00K | – |
See a number that looks wrong?